Last reviewed · How we verify
NCT06914557
Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy.
Phase 2 trial testing Scrambler Therapy in CIPN - Chemotherapy-Induced Peripheral Neuropathy in 50 participants. Currently enrolling.
30 March 2027
Quick facts
| Lead sponsor | Fox Chase Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 3 March 2025 |
| Primary completion | 30 March 2027 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Scrambler Therapy
- Questionnaire and Physical Exam — full drug profile →
Conditions studied
- CIPN - Chemotherapy-Induced Peripheral Neuropathy — all drugs for CIPN - Chemotherapy-Induced Peripheral Neuropathy →
- Pain — all drugs for Pain →
Sponsor
Fox Chase Cancer Center — full company profile →
Who can join
18 and older, any sex, with CIPN - Chemotherapy-Induced Peripheral Neuropathy or Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators hypothesize that Scrambler therapy with duloxetine, compared to duloxetine-based usual care, will result in greater improvement in CIPN as measured by the BPI-Short Form. In addition, the investigators will further assess pain using the EORTC CIPN-20 and determine whether Scrambler therapy results in improved levels of function as measured with the PDQ, and a decreased need for opioid medications. Our primary objective is to investigate whether Scrambler therapy with duloxetine is superior to duloxetine-based usual care in achieving at least a 50% reduction in pain scores, when comparing the cross-sectionally measured "average" pain score at day 35 to the cross-sectionally measured "average" pain score at baseline.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06914557
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Scrambler Therapy
Trials testing the same drug.
- NCT07174609 — Scrambler Therapy in Chronic Pancreatitis · NA · recruiting
- NCT05165901 — Clinical Effect of LG Medipain for Managing Chronic Pain Disorders · NA · recruiting
Other recruiting trials for CIPN - Chemotherapy-Induced Peripheral Neuropathy
Currently open trials in the same condition.
- NCT05121558 — The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy) · NA · active not recruiting
- NCT04917796 — The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy) · NA · active not recruiting
- NCT05928429 — Effects of Cryotherapy on Taxane-Induced Neuropathy in Patients With Breast Cancer · NA · recruiting
Other Fox Chase Cancer Center trials
Trials by the same sponsor.
- NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
- NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
- NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
- NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
- NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06914557 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
- Last refreshed: 9 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06914557.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing